Efficacy and safety of long-acting injectable risperidone in maintenance phase of bipolar and schizoaffective disorder;Eficacia y seguridad de risperidona inyectable de larga duración en fase de mantenimiento del trastorno bipolar y esquizoafeetivo

Actas Espanolas de Psiquiatria

Volumn 37, Issue 3, 2009, Pages 143-147

  Castro, P ^a   Sanchez Moreno J ^a   Martinez Aran A ^a   Salamero, M ^a   Murru, A ^a   Franco, C ^a   Vieta, E ^a   Benabarre, Antoni ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Adherence; Bipolar disorder; Long acting antipsychotic; Risperidone; Schizoaffective disorder

Indexed keywords

NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; FEMALE; HUMAN; INJECTION; MALE; MIDDLE AGED; PSYCHOSIS;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; RISPERIDONE; YOUNG ADULT;

EID: 75349100125     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Giblin MJ, Sweden J, Heller H, Hammen C, Relapase And impairment m bipolar disorder.AM J PSYCHIATRY 1996, 152:1635-4O.
2. GOODWIN G., VIETA L, EFFECTIVE MAINTENANCE TREATMENT BREAKING THE CYCLE OF BIPOLAR DISORDER, EURUPIAN PSYCHILA 2005, 20:365-71.
3. CHANGSU H, MOON-SOO L, CHI-UA P, YOUNG-HOON K, ASHWIN A P, ZN-KWA J, USEFULNESS OF LONG-ACTING INJECTIBLE TISPERIODONE during 12-month maintenance therapy of bipolar disorder. Progr Neuro-Psychopharmacol Biolog Psychiatry 2007;31: 1219-23.
4. Gopal S, Steffens DC, Kramer ML, Olsen MK. Symptomatic remission in patients with bipolar mania: results from a double- blind, placebo-controlled trial of risperidone monotherapy. J Clin Psychiatry 2005;66(8):1016-2O.
5. Perlis RH, Baker RW, Zarate Jr CA, Brown EB, Schuh LM, Jamal HH, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: A randomized, double- blind trial. J Clin Psychiatry 2006;67:1747-53.
6. Smulevich AB, Khanna S, Eerdekens M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: A 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol 2005; 15:75-84.
7. Vieta E, Brugue E, Goikolea JM, Sanchez-Moreno J, Reinares M, Comes M, et al. Acute and continuation risperidone monotherapy in mania. Hum Psychopharmacol 2004;19:41-5.
8. Savas HA, Yumru M, Ozen ME. Use of long-acting risperidone in the treatment of bipolar patients. J Clin Psychopharmacol 2006;26:530-1.
9. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978;133:429-35.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM), 1976; p. 218-22.
12. Lingjaerde 0, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987;334:1-10O.
13. Dias W, Brissos S, Carita Al. Clinical and neurocognitive correlates of insight in patients with bipolar I disorder in remission. Acta Psychiatr Scand 2008; 117(1):28-34.